Edition:
United States

Paratek Pharmaceuticals Inc (PRTK.OQ)

PRTK.OQ on NASDAQ Stock Exchange Global Market

6.26USD
13 Dec 2018
Change (% chg)

-- (--)
Prev Close
$6.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
158,268
52-wk High
$19.30
52-wk Low
$6.22

Chart for

About

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $227.24
Shares Outstanding(Mil.): 32.14
Dividend: --
Yield (%): --

Financials

  PRTK.OQ Industry Sector
P/E (TTM): -- 95.96 30.88
EPS (TTM): -3.64 -- --
ROI: -49.97 0.60 13.80
ROE: -141.53 -2.18 15.29

U.S. FDA panel backs approval of Paratek's antibiotic

A U.S. Food and Drug Administration expert panel on Wednesday voted in favor of approval of Paratek Pharmaceuticals Inc's antibiotic to treat bacterial pneumonia and skin infections.

Aug 08 2018

UPDATE 1-U.S. FDA panel backs approval of Paratek's antibiotic

Aug 8 A U.S. Food and Drug Administration expert panel on Wednesday voted in favor of approval of Paratek Pharmaceuticals Inc's antibiotic to treat bacterial pneumonia and skin infections.

Aug 08 2018

U.S. FDA panel backs approval of Paratek's antibiotic

Aug 8 A U.S. Food and Drug Administration expert panel on Wednesday voted in favor of approval of Paratek Pharmaceuticals Inc's antibiotic to treat bacterial pneumonia and skin infections.

Aug 08 2018

Paratek antibiotic not inferior to current treatments: FDA staff

Paratek Pharmaceuticals Inc's new antibiotic for bacterial pneumonia and skin infections is not inferior to current treatments, U.S. Food and Drug Administration staff reviewers said on Monday.

Aug 06 2018

UPDATE 1-Paratek antibiotic not inferior to current treatments-FDA staff

* Drug could bring in U.S. sales of $535 mln in 2025-analysts

Aug 06 2018

Earnings vs. Estimates